HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holt, P G Articles by Sly, P D Search for Related Content PubMed PubMed Citation Articles by Holt, P G Articles by Sly, P D

Thorax 2000;55:700-703 ( August )

Review series

Paediatric origins of adult lung diseases  2

Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs

P G Holt, P D Sly

TVW Telethon Institute for Child Health Research, Centre for Child Health Research, The University of Western Australia, Perth, Western Australia 6872

Correspondence to: Professor P G Holt email: patrick@ichr.uwa.edu.au

The first 150 words of the full text of this article appear below.

	Introduction

Current treatment regimens for asthma are based principally upon active suppression of inflammatory processes within airway tissues of sufferers, and one of the major thrusts of research in this area is towards development of increasingly more selective and more potent anti-inflammatory drugs. The impetus for much of the recent activity in relation to drug development in this field stems from an increased understanding of the contribution of immunologically mediated mechanisms towards inflammation induced tissue damage in the asthmatic airway, and this has led to the identification of a new spectrum of drug targets associated specifically with T helper 2 (Th2) cell functions.

However, we argue below that this overall drug development/testing process may be conceptually flawed, not in relation to drug design per se, but at the key stage of selection of subjects for subsequent clinical studies. In brief, we suggest that the practice of testing new selective anti-inflammatory and/or immunomodulatory . . . [Full text of this article]

This article has been cited by other articles:

				T Tschernig, V C de Vries, A S Debertin, A Braun, T Walles, F Traub, and R Pabst Density of dendritic cells in the human tracheal mucosa is age dependent and site specific Thorax, November 1, 2006; 61(11): 986 - 991. [Abstract] [Full Text] [PDF]

				H Milgrom Is there a role for treatment of asthma with omalizumab? Arch. Dis. Child., January 1, 2003; 88(1): 71 - 74. [Abstract] [Full Text] [PDF]

				S. D Message and S. L Johnston Viruses in asthma: The role of viruses in childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 29 - 43. [Abstract] [Full Text] [PDF]

				D. M. STEINBACHER and M. GLICK The dental patient with asthma: An update and oral health considerations J Am Dent Assoc, September 1, 2001; 132(9): 1229 - 1239. [Abstract] [Full Text] [PDF]

				T Tschernig, A S Debertin, F Paulsen, W J Kleemann, and R Pabst Dendritic cells in the mucosa of the human trachea are not regularly found in the first year of life Thorax, June 1, 2001; 56(6): 427 - 431. [Abstract] [Full Text]